In a report released today, Sam Eiber from BTIG reiterated a Buy rating on InMode (INMD – Research Report), with a price target of $25.00. The ...

Concepts Inc (NASDAQ:TMCI) received an upgrade from BTIG, with analyst Ryan Zimmerman changing the stock rating from Neutral to Buy and setting a new price target of $16.00. This upgrade comes after a ...

BTIG says shares of PayPal (PYPL) are down 10% following the Q4 due to high expectations rather than a structural issue in the company’s ...

BTIG analyst David Larsen adjusted the firm's stance on IQVIA Holdings (NYSE:IQV), moving from a Buy rating to Neutral. The $36.5 billion market cap company, currently trading near its 52-week low at ...

BTIG Research has recently reduced MGM Resorts International (MGM) stock to Neutral rating, as announced on February 3, 2025, according to Finviz. Earlier, on July 3, 2024, BTIG Research had initiated ...

Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...